Xcout Intelセルシード
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Subscribe to see セルシード’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
セルシード at a glance
セルシード is a biotech company headquartered in Tokyo, Japan. It is publicly listed (7776) with a market capitalisation of $58.1M.
セルシード competitors
A few of セルシード's closest competitors — see the full list of competitors and alternatives →
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based, and cell processing products. Furthermore, it offers contract development and manufacturing services, alongside expert consulting. The company, which was incorporated in 2017 and is based in Tokyo, Japan, previously operated under the name Cuore Inc. before adopting Cuorips Inc. in June 2017.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
CO.DON is a biopharmaceutical company specializing in tissue engineering and the development and manufacturing of personalized cell therapies. The company provides regenerative treatments for joint cartilage defects to medical professionals and patients.
Pharmicell develops and provides stem cell therapeutics, cell culture media, and biomedical products, alongside chemical raw materials and advanced industrial materials such as nucleosides and medical PEGs. The company serves patients, researchers, and medical institutions by offering stem cell-based treatments, contract development and manufacturing (CDMO) services, and stem cell-derived cosmetics.
ThermoGenesis Group, Inc. develops and commercializes automated cell processing systems, devices, and CDMO services for the cell and gene therapy industry. The company provides closed-system solutions for clinical biobanking, cellular processing, and manufacturing to support researchers, clinicians, and biomanufacturing organizations.
Get セルシード's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on セルシード in Xcout Intel
- The full competitor set, tracking, exports and API access